Market Analysis - Cell Signaling 2017
American Cell Signaling and Cancer Therapy Market Analysis and Reports | USA Conference Series
Cell signaling and cancer therapy is a Major Field in modern medical Practice and Diagnosis. Cell signaling and cancer therapy is bound with the system biology, computational biology, genomics proteomics, metabolomics, drug designing clinical trials, bacterial pathogenesis and microbial immunization. This field includes the Cell Identification, Cell Viability, Cell Signaling Pathway/Signal Transduction, Cell Proliferation, Cell Interaction, Target Identification and Validation, Single-cell Analysis. Cell signaling and cancer therapy includes the investigation of the harming effect of ailment on cells and tissues and the route in which the body looks to secure and repair itself. The global cell analysis market is expected to reach USD 26.0 Billion by 2020 from USD19.0 Billion in 2015, growing at a CAGR of 6.56% from 2015 to 2020. Protein therapeutics already has an important role in almost every field of medicine, but this role is still only in its infancy.
The global market of signal transduction therapies/inhibitors (JAK and PI3K) reached $173.5 million in 2012. This market is expected to grow to $464.5 million in 2013 and $2.2 billion in 2018 with a compound annual growth rate CAGR of 36.8% over the five-year period from 2013-2018. The global cell-based assays market is expected to grasp USD 18,329.37 Million by 2020 from USD 10,799.53 Million in 2015, growing at a CAGR of 11.16% between 2015 and 2020. The global pharmaceutical industry is expected to rise at a CAGR between 7% and 12% in the forecast period 2014 to 2019.The global oncology drug market is expected to reach $ 150 billion by 2020 from $ 107 billion in 2015 entering annual growth rate of 7.5-10.5 percent through 2020, according to a new study. The global Cancer/Tumor Profiling market is poised to reach USD 61.87 Billion by 2021 from USD 25.82 Billion in 2016, at a CAGR of 19.1% from 2016 to 2021.The global market for spinal and neurostimulation intervention products is estimated to reach $15.8 billion by 2021 from $12.6 billion in 2016, increasing at a compound annual growth rate CAGR of 4.5% from 2016 through 2021. The global cell and tissue analysis products market reached $10.8 billion in 2015 and should reach about $12.5 billion by 2020, with a compound annual growth rate CAGR of 2.8% by 2020. The global G protein, coupled receptors GPCR targeting drug market sharply fell in the last three years by virtue of an array of patent expirations of blockbuster products. The market abated from nearly $111 billion to almost $100 billion with a -3.4% compound annual growth rate CAGR between 2010 & 2013. With the introduction of novel pharmaceuticals and newly emerging classes of drugs, BCC Research expects this market to reach $114 billion by 2018, a CAGR of 2.7% from 2013-2018. Prominent players in the cell market are BD Biosciences, Danaher Corporation, GE Healthcare, Miltenyi Biotec, pluriSelect , STEMCELL Technologies , Sigma-Aldrich Corporation and Thermo Fisher Scientific, Inc. Protein Biomarkers, Recombinant protein drugs, Protein gold standards, Protein expression services and market analysis, Fusion protein therapeutics are the many applications and sources for Protein Therapeutics & Market Analysis. Cell based assays market by application graph shown in Figure 1 in which Drug discovery has more value than other applications. Basic research and ADME studies comparatively less value than Drug Discovery.
Fig 1: Cell-based Assays Market by Application
North America commands the cell analysis market with the U.S. accounting for a major market share. However, Asia-Pacific is poised to grow at the highest CAGR during the forecast period owing to raising government investments in the life sciences sector, rapidly expanding biotechnology and biopharmaceutical industries in this region. For detail, The Global Health Innovative Technology Fund (GHIT Fund) is a public-private partnership committed towards Japanese R&D focusing on research related to infectious diseases. The big drivers for the market include raising R&D spending on research, benefits of cell-based assays over other methods, their raising adoption in drug discovery, and advancements in automation and high-throughput techniques will aid market growth. Emerging economies are making huge investments in R&D as opportunities in basic research and drug discovery are big and growing very speedily. It is the fastest expanding area of the industry. The interest for life science products in emerging Asian nations such as China and India is growing at a robust rate compared to developed countries.
According to drug class, the industry is classified into five major segments, like, anti-metabolites, HER2 inhibitors, aromatase inhibitors, mitotic inhibitors, and hormone receptors. Key players in the breast cancer therapeutics market include AstraZeneca, Eisai, Eli Lilly and Company, GlaxoSmithKline, Novartis International AG, Puma Biotechnology and Teva Pharmaceutical Industries. Genentech subsidized over 60% to the overall breast cancer therapeutics market share in 2015. Prostate cancer is the second popular cause of new cancer cases in men worldwide and the sixth popular cause of cancerous death in men. Globally, about 899,000 men were diagnosed with prostate cancer in 2008 and it is evaluated that this number will get doubled (1.7 million) by 2030.
Cancer Biological Therapy Market size is expected to reach USD 100 billion by 2023; as per a new research report by Global Market Insights, Increasing incidence rates and increased adoption of biologic therapy will drive global cancer biological therapy market size It is estimated by the ACS that 180,890 prostate cancer and 246,660 breast cancer cases will be diagnosed in 2016 in the U.S. Cancer growth blockers market was over USD 18 billion in 2015, and is expected to rise at 5.8% CAGR from 2016 to 2023. Bispecific monoclonal antibodies are anticipated to grow at 6.5% CAGR from 2016 to 2023. The global Cancer therapy market is estimated to grow at 17.6% CAGR to reach $52.2billion by 2021. Breast cancer therapy is the largest market expected to reach $30.8 billion by 2016 at an estimated CAGR of 15%. Breast Cancer Therapeutics Market size was admired at over USD 7.5 billion in 2015 and is expected to observer growth to surpass USD 16 billion by 2023. High degree of competition, rising number of medication options, and substitute branded drugs availability may adversely impact revenue in the coming years. Global prostate cancer therapeutics market was admired at $2,713 million in 2010 and it is expected to reach $6,457 million, by 2020. It is evaluated that the market will rise at a CAGR of 11.4% and 6.8% from 2010-2015 & 2015-2020 respectively. By therapy, hormonal therapy is commanding the global prostate cancer drugs market with 66% market share in 2010 and predicted to account for 53% market share in 2020. Cancer Therapeutics market rate shown in the Figure 2 in which different countries has different therapeutics rate like Japan has more therapeutics rate than the other countries.
Fig 2: Cancer Therapeutics market rate in millions
Acceleration in cancer incidences and access to modern therapeutics, population of aged people, Rise in innovations, improvements and approvals promote growth of the market. Furthermore, efficiency and High process magnetize manufactures also devote to the growth of the market. Major restraints are high price of therapies, change in reimbursement policies, and challenges faced in clinical trials. Oncology spending concentrated to America and Europe which totally accounts for 65% of the total market. Targeted therapies have increased their share of global oncology from 11 percent to 46 percent last year.
Annual Summit on Cell Signaling and Cancer Therapy is bustling to be held at Chicago, USA during September 27-28, 2017 hosted by Conferences Series. Through the theme "To Frame An Admiring Portal For Pioneering Cancer Therapy and Cell Signaling Findings", conference will explore the advances in Medical Approaches, Oncology, Translational Oncology, Computational Technologies, etc. This conference brings a novel and International mixture of giant and medium cancer therapy and cell signaling analysis, leading universities and cancer analysis establishments creating the conference an excellent platform to share expertise, foster collaborations across trade and world, and assess rising technologies across the world.